勤浩医药递表港交所

Group 1 - The core point of the article is that Qinhau Pharmaceutical (Suzhou) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - As of January 7, 2026, the company has a pipeline that includes seven self-developed drug candidates, comprising four in clinical stages, one approved by the National Medical Products Administration of China and the FDA, and two in preclinical stages [1] - The company focuses on developing innovative drug candidates targeting the RAS signaling pathway and synthetic lethality mechanisms, with several candidates being globally leading in clinical progress for the same target [1]